<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01714596</url>
  </required_header>
  <id_info>
    <org_study_id>METRC POvIV</org_study_id>
    <nct_id>NCT01714596</nct_id>
  </id_info>
  <brief_title>Randomized Trial to Assess PO Versus IV Antibiotics</brief_title>
  <acronym>POvIV</acronym>
  <official_title>A Prospective Randomized Trial to Assess PO Versus IV Antibiotics for the Treatment of Post-op Wound Infection After Extremity Fractures (POvIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Major Extremity Trauma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Major Extremity Trauma Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the effect of treatment of post-op wound infection in
      long bones after fracture fixation or joint fusion and either: (Group 1) operative
      debridement and PO antibiotic treatment for 6 weeks; or (Group 2) operative debridement and
      IV antibiotics for 6 weeks.

      Primary Hypothesis: The rate of treatment failure by one year in Group 1 will be non-inferior
      to the rate in Group 2. Treatment failure is defined as wound problems that require surgery
      &gt;2 weeks after initial debridement, infection recurrence, infection with a new pathogen,
      joint erosion, implant failure, medical problems related to the treatment administration
      which necessitates a switch from one arm to the other.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not provided here. Details listed above.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">August 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective: investigate the efficacy of oral (PO) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures or joint fusions.</measure>
    <time_frame>4 Years</time_frame>
    <description>Phase III randomized controlled clinical trial to investigate efficacy of PO vs. IV antibiotics in the treatment of post-operative wound infections. Clinical efficacy will be measured by the incidence of treatment failure within the first one-year of follow-up as defined by culture positive recurrence of infection prior to bony union, progressive radiographic plate loosening, joint erosion due to infection that results in amputation or joint fusion, development of adverse reactions to antibiotics that cause change in form of administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Adherence</measure>
    <time_frame>4 Years</time_frame>
    <description>Patient adherence with PO antibiotics will be monitored through wireless-enabled microchip monitors embedded in pill bottles. The Home Health agency administering the IV antibiotics will be contacted to assess adherence with IV antibiotic regimen by assessing utilization of supplied antibiotics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>Oral Antibiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Antibiotic Arm; Participants assigned to this group will receive oral antibiotics as prescribed by their treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Antibiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to this group will receive intravenous (IV) antibiotics as prescribed by their treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PO versus IV antibiotics Route of administration evaluation</intervention_name>
    <description>This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.</description>
    <arm_group_label>Oral Antibiotic</arm_group_label>
    <arm_group_label>IV Antibiotic</arm_group_label>
    <other_name>based on local practices and bacterial susceptibilities</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with any fractures of any bone at or proximal to and including the
             tarsal/metatarsal joint (Lisfranc) or proximal to the carpal joints (includes distal
             radius fractures), excluding the spine, treated with any type of internal fixation, or

          2. Patients undergoing fusion of any bone at or proximal to and including the subtalar
             joint or radial carpal joint, (excluding the spine) that develop a post op wound
             infection at any time.

          3. Patients diagnosed with a wound infection of the study injury, defined as patients
             with at least one of the following:

               1. Deep culture positive after operative debridement.

               2. Cultures positive in thio only after operative debridement.

               3. Negative culture after operative debridement if wound infection meets the Center
                  for Disease control and Prevention (CDC) criteria.

          4. Patients who are English or Spanish competent.

          5. Patients aged 18 - 84.

          6. Patients with bacteria susceptible to both PO and IV antibiotics.

          7. Patients able to be treated for their infection at the METRC facility for at least 12
             months following definitive surgical procedure

          8. Patients may have multiple eligible study-eligible injuries.

          9. Patients may have temporary external fixation prior to definitive fixation.

         10. Patients may have received antibiotics prior to operative wound debridement.

         11. Patient is able to obtain study medication(s).

         12. Patient may be pregnant at the time of screening.

        Exclusion Criteria:

          1. Patients who have high risk of amputation of the study limb (based on opinion of the
             initial managing physician).

          2. Patients undergoing treatment with any other investigational therapy within the month
             preceding implantation or planned within the 12 months following implantation.

          3. Patients with history of chronic infection at the site of study injury, defined as:

             patients with chronic osteomyelitis identified by radiographic erosion or sequestrum;
             or patients with more than one instance of surgical treatment of infection and
             approximately 6 week course of antibiotics.

          4. Patients with pathological fractures; a known history of Paget's disease.

          5. Patients for whom the definitive treatment of the study injury was an external
             fixator.

          6. Patients who are currently on Selective Serotonin Reuptake Inhibitor (SSRI) medication
             (e.g. Zoloft, Prozac, Celexa), and bacteria is MRSA

          7. Patients with cultures positive in thio only.

          8. Patients who are incarcerated or who have unstable housing situations due to concerns
             regarding ability to receive home care, adherence phone calls, and maintain follow up.
             .

          9. Patients or designated proxy who are unwilling to provide consent.

         10. Patients with a history of IV drug use who in the investigator's opinion are
             unsuitable candidates for IV therapy.

         11. Patients likely to have severe problems maintaining follow-up, including patients
             diagnosed with a severe psychiatric conditions, patients who live too far outside the
             hospital's catchment area.

         12. Patients with traumatic brain injury or who are intellectually challenged and who lack
             adequate family support to ensure adherence to the protocol.

         13. Patients unable to swallow oral medications or without adequately functioning GI
             tract.

         14. Patients who, based upon the clinical judgment of the treating clinician, are NOT
             equally suited for treatment with either oral or intravenous antibiotics (i.e., those
             for whom there is a clinical treatment preference).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William T Obremskey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renan Castillo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tara Taylor, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Remenapp, MS</last_name>
    <phone>410-614-3576</phone>
    <email>cremena1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tara Taylor, MPH</last_name>
    <email>ttaylo56@jhu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asya Love</last_name>
      <email>asyalove@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Candice Dubose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goran Stankovic</last_name>
      <email>goran.stankovic@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Charles Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Berhaneselase</last_name>
      <email>Eleni.Berhaneselase@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Saam Morshed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Miclau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Health and Hospital Authority</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Nadeau</last_name>
      <email>Jason.Nadeau@dhha.org</email>
    </contact>
    <investigator>
      <last_name>Cyril Mauffrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Ryder Trauma Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dinorah Rodriquez</last_name>
      <email>dinorah@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Zych, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eskenazi Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Moore</last_name>
      <email>momfreed@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Mullis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Fruehling</last_name>
      <email>catherine-fruehling@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>J Lawrence Marsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland R Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Degani</last_name>
      <email>ydegani@umoa.umm.edu</email>
    </contact>
    <investigator>
      <last_name>Robert O'Toole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Silva</last_name>
      <email>Heather.Silva@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Paul Tornetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JR Westberg</last_name>
      <email>Jerald.Westberg@hcmed.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Dawson</last_name>
      <email>sdawson@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Cannada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella Bianco</last_name>
      <email>Isabella.Bianco@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Sanjit Konda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella Bianco</last_name>
      <email>Isabella.Bianco@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Sanjit Konda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Churchill</last_name>
      <email>Christine.Churchill@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Catherine Passaretti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Holden</last_name>
      <email>mholden@wfubmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Halvorson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Breslin</last_name>
      <email>mbreslin@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Heather Vallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State University M.S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Horne</last_name>
      <email>ahorne@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>J. Spence Reid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Trochez</last_name>
      <email>karen.m.trochez@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>William T. Obremskey, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center (SAMMC)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Kimmel</last_name>
      <email>joseph.e.kimmel2.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Dan Stinner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric McVey</last_name>
      <email>EDM9U@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>David Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lolita Ramsey</last_name>
      <email>lolita.ramsey@inova.org</email>
    </contact>
    <investigator>
      <last_name>Robert Hymes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorie Gower</last_name>
      <email>lorie.m.gower.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Christopher Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington/Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Agel</last_name>
      <email>bagel@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Reza Firoozabadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Siy</last_name>
      <email>Siy@ortho.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Whiting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2012</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Antibiotic</keyword>
  <keyword>Intravenous Antibiotic</keyword>
  <keyword>Wound infection</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

